Houri Esmaeilkhanian

Houri Esmaeilkhanian

Auto-generated profile, based on publicly available information

Houri Esmaeilkhanian

Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YHYe He
Ye He
AVAditya Verma
Aditya Verma
MNMuneeswar G. Nittala
Muneeswar G. Nittala
SVSwetha Bindu Velaga
Swetha Bindu Velaga
HEHouri Esmaeilkhanian
Houri Esmaeilkhanian
SSSRINIVAS R SADDA
SRINIVAS R SADDA

1 March 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
HEHouri Esmaeilkhanian
Houri Esmaeilkhanian
KGKaren G Gutierrez
Karen G Gutierrez
DMDavid Myung
David Myung
AFAnn Caroline Fisher
Ann Caroline Fisher
Purpose: To evaluate the use of an autonomous artificial intelligence (AI)-based device to screen for diabetic retinopathy (DR) and to evaluate the frequency of diabetes mellitus (DM) and DR in an under-resourced population served by the Stanford Belize Vision Clinic (SBVC). Patients and Methods: The records of all patients from 2017 to 2024 were collected and analyzed, dividing the study into two time periods: Pre-AI (before June 2022, prior to the implementation of the LumineticsCore® device at SBVC) and Post-AI (from June 2022 to the present) and subdivided into post-COVID19 and pre-COVID19 periods. Patients were categorized based on self-reported past medical history (PMH) as DM positive (diagnosed DM) and DM negative (no PMH of DM). AI camera outcomes included: negative for more than mild DR (MTMDR), positive for MTMDR, and insufficient exam quality. Results: A total of 1897 patients with a mean age of 47.6 years were included. The gradability of encounters by the AI device was 89.1%. The frequency of DR detection increased significantly in the Post-AI period (55/639) compared to the Pre-AI period (38/1258), including during the COVID-19 pandemic. The mean age of DR diagnosis was significantly lower in the Post-AI period (44.1 years) compared to Pre-AI period (60.7 years) among DM negative patients. There was a significant association between having DR and hypertension. Additionally, the detection rate of DM increased in the Post-AI period compared to Pre-AI period. Conclusion: Autonomous AI-based screening significantly improves the detection of patients with DR in areas with limited healthcare resources by reducing dependence on on-field ophthalmologists. This innovative approach can be seamlessly integrated into primary care settings, with technicians capturing images quickly and efficiently within just a few minutes. This study demonstrates the effectiveness of autonomous AI in identifying patients with both DR and DM, as well as associated high-burden diseases such as hypertension, across various age ranges. Plain Language Summary: Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus (DM) and a leading cause of blindness worldwide, ranking as the third leading cause of blindness in Belize. DR screening is crucial for timely diagnosis and intervention. Belize, a healthcare resource-limited country in Central America, faces significant challenges in managing DR due to the reliance on ophthalmologists from other countries, which places a heavy burden on both patients and the healthcare system. Implementing fully autonomous artificial intelligence (AI) for DR screening is a significant step towards improving eye healthcare accessibility and enhancing DR detection. In our study, the deployment of an AI-based image analysis technologyin Ambergris Caye, Belize, which previously relied on volunteer ophthalmologists, significantly increased the rate of DR screening. This AI-driven approach not only improved the detection of DR but also identified previously undiagnosed cases of DM. The impact of this technology was particularly pronounced with the COVID-19 pandemic when travel restrictions impeded visiting volunteer physicians. This approach is a game-changer for resource-limited areas, dramatically enhancing eye care access and advancing health equity.